• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C†‡

  1. Robert J. Fontana1,§,*,
  2. Linas A. Bieliauskas2,3,
  3. Karen L. Lindsay4,
  4. Carla Back-Madruga5,
  5. Elizabeth C. Wright6,
  6. Kristin K. Snow7,
  7. Anna S.F. Lok1,
  8. Ziad Kronfol2,
  9. Latha Padmanabhan7

Article first published online: 26 APR 2007

DOI: 10.1002/hep.21633

Issue

Hepatology

Hepatology

Volume 45, Issue 5, pages 1154–1163, May 2007

Additional Information

How to Cite

Fontana, R. J., Bieliauskas, L. A., Lindsay, K. L., Back-Madruga, C., Wright, E. C., Snow, K. K., Lok, A. S.F., Kronfol, Z. and Padmanabhan, L. (2007), Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology, 45: 1154–1163. doi: 10.1002/hep.21633

Author Information

  1. 1

    Division of Gastroenterology, Department of Internal Medicine, Department of Psychiatry, University of Michigan, Ann Arbor, MI

  2. 2

    Neuropsychology Section, Department of Psychiatry, University of Michigan, Ann Arbor, MI

  3. 3

    Psychology Service, Veterans Affairs Health System, Ann Arbor, MI

  4. 4

    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA

  5. 5

    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA

  6. 6

    Office of the Director, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

  7. 7

    New England Research Institutes, Watertown, MA

  1. §

    fax: 734-936-7392

*3912 Taubman Center, Ann Arbor, MI 48109-0362

  1. †

    This is publication number 22 from the HALT-C Trial Group.

  2. ‡

    Potential conflict of interest: Dr. Fontana is in the speakers' bureau of Roche Pharmaceutical and Bristol-Myers Squibb. Dr. Lindsay received grants from and advises for Hoffmann-LaRoche, Inc., and Valeant Pharmaceuticals. She also received grants Schering-Plough Corp., Scripps Clinic Liver Research Consortium, and Idenix Pharmaceuticals, Inc. She advises for Gilead Sciences, Roche Diagnostics, Quest Lab., Amgen Corporation, Invesek, Bristol Myers Squibb, Charles River Lab., iMedOptions, Zymogenetics, Inc., Peregrine Pharmaceuticals, Inc., and Kendle International. She is a consultant for Fujisawa Research Institute of America, Inc., GlaxoSmithKline, Wellpoint Pharmacy Management, Aventix Pharmaceuticals, Inc., and Medtronics.

  3. §

    fax: 734-936-7392

Publication History

  1. Issue published online: 26 APR 2007
  2. Article first published online: 26 APR 2007
  3. Manuscript Accepted: 22 DEC 2006
  4. Manuscript Received: 10 OCT 2006

Funded by

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Cancer Institute
  • National Center for Minority Health and Health Disparities
  • General Clinical Research Center grants from the National Center for Research Resources
  • National Institutes of Health
  • Hoffmann-La Roche, Inc.
  • Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases, Division of Digestive Diseases and Nutrition
  • University of Southern California, Los Angeles, CA. Grant Numbers: N01-DK-9-2325, M01RR-00043
  • University of Michigan Medical Center, Ann Arbor, MI. Grant Numbers: N01-DK-9-2323, M01RR-00042
  • New England Research Institutes, Watertown, MA. Grant Number: N01-DK-9-2328

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (271K)

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–965.
  • 2
    Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140; 346–355.
  • 3
    Shifffman ML, DiBisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126: 1015–1023.
  • 4
    Lee SS, Peltekian K, Krajdens M, Yoshida EM, Deschenes M, Heathcote EJ, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40kD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397–408.
    Direct Link:
  • 5
    Fried MW, Russo MA. Side effects of antiviral therapy for hepatitis C. Gastroenterology 2003; 124: 1711–1719.
  • 6
    Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18; 107–116.
  • 7
    Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EZ, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847–854.
  • 8
    Weissenborn K, Krause J, Bokemyer M, Hecker H, Schuler A, Anen JC, et al. Hepatitis C virus infection affects the brain: evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845–851.
  • 9
    Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok ASF, et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005; 43: 614–622.
  • 10
    Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433–439.
    Direct Link:
  • 11
    McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801–808.
    Direct Link:
  • 12
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C trial: pegylated interferon as a maintenance therapy for chronic hepatitis C in previous Interferon nonresponders. Control Clin Trials 2004; 25: 472–492.
  • 13
    Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252; 938–941.
  • 14
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672–676.
  • 15
    Wittchen HU. Reliability and validity studies of the WHO composite international diagnostic interview: a critical review. J Psychiatr Res 1994; 28: 57–84.
  • 16
    Skinner HA, Sheu WJ. Reliability of alcohol use indices: the lifetime drinking history and the MAST. J Stud Alcohol 1982; 43: 1157–1170.
  • 17
    Bieliauskas L, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok ASF, et al. Clinical relevance of cognitive scores in patients with advanced fibrosis. J Clin Exp Neuropsychol 2006; 28: 1346–1361.
  • 18
    McCaffrey RJ, Ortega A, Orsillo SM, Nelles WB, Haase RF. Practice effects in repeated neuropsychological assessments. Clin Neuropsychol 1991; 6: 32–42.
  • 19
    Zachary RA. Shipley institute of living scale. Los Angeles: Western Psychological Services, 1991: 1–35.
  • 20
    Beck AT, Steer RA, Brown GK. BDI-II Manual. The Psychological Corporation. San Antonio, TX: Harcourt Brace and Company, 1996: 1–20.
  • 21
    Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med 1983; 3: 595–605.
  • 22
    U.S. Census Bureau, Population Division, Education & Social Stratification Branch. Maintained by: Information & Research Services Internet Staff (Population Division). Created: March 15, 2004.
  • 23
    Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis RJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology 1995; 45: 947–950.
  • 24
    Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26: 596–600.
  • 25
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961–966.
  • 26
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672–676.
  • 27
    Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000; 152: 383–389.
  • 28
    Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006; 41: 577–585.
  • 29
    Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, et al. Neurotoxicity of interferon-a in melanoma therapy: results from a randomized controlled trial. Cancer 1998; 83; 482–489.
    Direct Link:
  • 30
    Mapou RL, Law WA, Wagner K, Malone JL, Skillman DK. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996; 8: 74–81.
  • 31
    Amodio P, De Toni EN, Cavalletto L, Mapelli D, Bernardinello E. Del Piccolo F, et al. Mood, cognition and EEG changes during interferon α (alfa-IFN) treatment for chronic hepatitis C. J Affect Disord 2005; 84: 93–98.
  • 32
    Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon a on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005; 11: 16–22.
  • 33
    Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9: 419–428.
  • 34
    Lemay S, Bedard M, Roleau I, Tremblay P. Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects. Clin Neuropsychol 2004; 18: 284–302.
  • 35
    McCaffrey RJ, Ortega A, Orsillo SM, Neiles WB, Haase RF. Practice effects in repeated neuropsychological assessment. Clin Neuropsychol 1992; 6: 32–42.
  • 36
    Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol 1985; 7: 251–263.
  • 37
    Basso MR, Bornstein RA, Lang JM. Practice effects of commonly used measures of executive function across twelve months. Clin Neuropsychol 1999; 13: 283–292.
  • 38
    Beglinger LJ, Crawford-Miller, Kareken DA. Neuropsychological practice effects and change detection in people with schizophrenia. Schizophr Res 2003; 62: 191–194.
  • 39
    Paradee CV, Rapport LJ, Hanks RA, Levy JA. Circadian preference and cognitive functioning among rehabilitation inpatients. Clin Neuropsychol 2005; 19: 55–72.
  • 40
    Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al. Depression, anemia, and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491–498.
  • 41
    Benedict RHB, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 2004; 10: 675–678.
  • 42
    Randolph JJ, Arnett PA, Freske P. Metamemory in multiple sclerosis: Exploring affective and executive contributors. Arch Clin Neuropsychol 2004; 19: 259–279.
  • 43
    Elixhauser A, Leidy NK, Meador K, Means E, Willan MK. The relationship between memory performance, perceived cognitive function and mood in patients with epilepsy. Epilepsy Res 1999; 37: 13–24.
  • 44
    Banos JH, LaGory J, Sawrie S, Faught E, Knowlton R, Prasad A, et al. Self-report of cognitive abilities in temporal lobe epilepsy:cognitive, psychosocial, and emotional factors. Epilepsy Behav 2004; 5: 575–579.
  • 45
    Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38–39.
  • 46
    Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Knguid C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 600–608.
  • 47
    Mayr N, Zeithofer J, Deecke L, Fritz E, Ludwig H, Gisslinger H. Neurological function during long-term therapy with recombinant interferon-alpha. J Neuropsychiatry Clin Neurosci 1999; 11: 343–348.
  • 48
    Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive function in multiple sclerosis. Eur Neurol 2002; 47: 11–14.
  • 49
    Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann HL, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006; 55: 1624–1630.
  • 50
    Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-a induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538–544.
View Full Article (HTML) Get PDF (271K)